Ziel Biopharma

Ziel Biopharma was an Irish biopharmaceutical company focused on encapsulation technologies for living cells and biologically active agents. Its core approach used cellulose sulfate-based microcapsules to enable therapeutic cell encapsulation and delivery, including a pancreatic cancer program involving cytochrome P450 isoform 2B1 gene-transfected human embryonic kidney 293 cells used with ifosfamide. The company also associated its technology with the NovaCaps brand and patent filings covering cellulose sulfate manufacturing and encapsulation methods. Publicly available corporate records indicate the company was dissolved in 2022, and there is limited evidence of an active late-stage development pipeline.